Effective binding of a phosphatidylserine-targeting antibody to ebola virus infected cells and purified virions

Stuart Dowall; V. A. Graham; K. Corbin-Lickfett; C. Empig; K. Schlunegger; C. B. Bruce; L. Easterbrook; R. Hewson

doi:10.1155/2015/347903

Effective binding of a phosphatidylserine-targeting antibody to ebola virus infected cells and purified virions

Stuart Dowall^*
, V. A. Graham
, K. Corbin-Lickfett
, C. Empig
, K. Schlunegger
, C. B. Bruce
, L. Easterbrook
, R. Hewson

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.

Original language	English
Article number	347903
Journal	Journal of Immunology Research
Volume	2015
DOIs	https://doi.org/10.1155/2015/347903
Publication status	Published - 2015

Bibliographical note

Publisher Copyright:
© 2015 S. D. Dowall et al.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1155/2015/347903

Cite this

@article{a0c2af4445384f22aa32024124c2ee54,

title = "Effective binding of a phosphatidylserine-targeting antibody to ebola virus infected cells and purified virions",

abstract = "Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90\%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.",

author = "Stuart Dowall and Graham, \{V. A.\} and K. Corbin-Lickfett and C. Empig and K. Schlunegger and Bruce, \{C. B.\} and L. Easterbrook and R. Hewson",

note = "Publisher Copyright: {\textcopyright} 2015 S. D. Dowall et al.",

year = "2015",

doi = "10.1155/2015/347903",

language = "English",

volume = "2015",

journal = "Journal of Immunology Research",

issn = "2314-8861",

publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Effective binding of a phosphatidylserine-targeting antibody to ebola virus infected cells and purified virions

AU - Dowall, Stuart

AU - Graham, V. A.

AU - Corbin-Lickfett, K.

AU - Empig, C.

AU - Schlunegger, K.

AU - Bruce, C. B.

AU - Easterbrook, L.

AU - Hewson, R.

PY - 2015

Y1 - 2015

N2 - Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.

AB - Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.

UR - https://www.scopus.com/pages/publications/84925307941

U2 - 10.1155/2015/347903

DO - 10.1155/2015/347903

M3 - Article

C2 - 25815346

AN - SCOPUS:84925307941

SN - 2314-8861

VL - 2015

JO - Journal of Immunology Research

JF - Journal of Immunology Research

M1 - 347903

ER -

Effective binding of a phosphatidylserine-targeting antibody to ebola virus infected cells and purified virions

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this